Podcasts about therapeutics

Biotech might produce the world's next trillion-dollar company—and Simba Gill and Steve Ledger are betting on it. Join Jess Larsen as he explores how Serina Therapeutics' drug optimization platform could reshape the future of treatment for Parkinson's, cancer, and beyond. Simba, with four decades of biotech leadership, and Steve, with roots in finance and venture, share how science, capital, and mission come together to drive massive impact. This is a behind-the-scenes look at what happens when breakthrough science collides with visionary leadership. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospital Diabetes and Metabolic Care Center, discuss the recently published results of the ATTAIN-1 and STEP UP clinical trials, both of which were presented at the European Association for the Study of Diabetes (EASD) 2025 Conference. 00:00:00 Introduction 00:00:32 ATTAIN-1 00:04:07 GLP-1s as a Daily Pill 00:08:20 Possible Lower GLP-1 Prices 00:09:03 STEP UP 00:11:41 Cardiovascular Protection with GLP-1s 00:12:48 GI Side Effects of Semaglutide 7.2 00:16:16 3 Times the Dose, 3 Times the Cardiovascular Protection? 00:17:20 Outro

In this episode of PodMD, General Ophthalmologist Dr Jerome Ha will be discussing the topic of Therapeutics for Optometrists: Cataract Surgery (Dry-Eye and Post-Op Eye Drops).

23. september 2025 I dag har vi med oss CEO Jørund Sollid i Immuvera Therapeutics. Selskapet het Alv B tidligere, og utvikler behandling av kreft hos hunder. De skal inn i en randomisert studie på starten av 2026 som, om dataene er gode, kan lede til en markedsgodkjennelse i 2029. Selskapet skal i disse dager hente penger, og du finner mer info om dette på selskapets Linked.In eller Folkeinvest.

In this episode, Jacob sits down with Joshua Meier, co-founder of Chai Discovery and former Chief AI Officer at Absci, to explore the breakthrough moment happening in AI drug discovery. They discuss how the field has evolved through three distinct waves, with the current generation of companies finally achieving success rates that seemed impossible just years ago.  The conversation covers everything from moving drug discovery out of the lab and into computers, to why AI models think differently than human chemists, to the strategic decisions around open sourcing foundational models while keeping design capabilities proprietary. It's an in-depth look at how AI is fundamentally changing pharmaceutical innovation and what it means for the future of medicine. Check out the full Chai-2 Zero-Shot Antibody report linked here: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf (0:00) Intro(1:25) The Evolution of AI in Drug Discovery(5:14) Current State and Future of AI in Biotech(10:08) Challenges and Modalities in Therapeutics(14:44) Data Generation and Model Training(22:52) Open Source and Model Development at Chai(29:52) Open Source Models and Their Impact(34:36) How Should Chai-2 Be Used?(38:53) The Future of AI in Pharma and Biotech(42:46) Key Milestones and Metrics in AI-Driven Drug Discovery(47:20) Critiques and Hesitation(54:01) Quickfire Out-Of-Pocket: https://www.outofpocket.health/

Send us a textBilu Huang ( https://biluhuang.com/ ) is a visionary scientist dedicated to finding solutions to some of the most pressing challenges facing humanity. His interdisciplinary work spans multiple fields, including biological aging, dinosaur extinction theories, geoengineering for carbon removal, and controlled nuclear fusion technology.Born in Sanming City, Fujian Province, Huang is an independent researcher whose knowledge is entirely self-taught. Driven by curiosity and a relentless pursuit of scientific exploration, he has achieved numerous research results through his dedication and passion for science.As a talented theoretical gerontologist,  he proposed the Telomere DNA and ribosomal DNA co-regulation model for cell senescence (TRCS) and he is now using this latest theory to develop biotechnology to rejuvenate cells which will be used to completely cure various age-related degenerative diseases and greatly extend human life at Fuzhuang Therapeutics ( https://lab.fuzhuangtx.com/en/ ).#Aging #Longevity #BiluHuang #FuzhuangTherapeutics #TelomereDNAAndRibosomalDNACoRegulationModelForCell #Senescence #TRCS #DinosaurExtinctionResearch #CarbonRemovalTechnology #ControlledNuclearFusion #TelomereDNA #RibosomalDNA #CellularAging #GeneticProgram #Telomere #P53#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

What if we could treat debilitating diseases by listening in on the "secret, invisible language" of worms? In this groundbreaking episode, we talk with Dr. Andrea Choe, Co-Founder and CEO of Holoclara, who uncovered a "universal worm language" used for hundreds of millions of years. Dr. Choe reveals how our modern "aggressive hygiene routine" removed the worms we co-evolved with, leading to a rise in allergic and autoimmune diseases. Discover how her team is pioneering a new class of safe, orally available therapies by synthesizing worm-derived molecules that "rebalance" our immune systems and have already blocked disease in animal models. This is a fascinating journey from a fundamental discovery in evolutionary biology to the cutting edge of biotech innovation.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at www.messaginglab.com/groweverythingChapters:(00:00:00) Welcome to Grow Everything Podcast(00:00:18) NYC Biotech and Climate Week Recap(00:08:43) Science News: Comets and Octopuses(00:15:17) Meet Dr. Andrea Choe(00:15:52) From Researcher to Founder: The Call to Action(00:17:25) Discovering the Universal "Worm Language"(00:25:11) Connecting Worm Secretions to Therapeutics(00:29:49) How Modern Hygiene Created an Immune Imbalance(00:34:35) Navigating the Hurdles of Natural Medicine(00:38:50) Holoclara's Mission to Treat Eosinophilic Esophagitis (EoE)(00:42:25) Holoclara's Phase 1 Safety and Trial Results(00:51:03) Moonshot Vision: A "Worm Atlas" of Molecules(00:52:28) The Strategy for Patenting Natural Molecules(00:54:33) Worm Superpowers & Immune Myths(00:58:25) Reflecting on Nature's Untapped Answers(01:02:41) Coming Up on Grow EverythingEpisode Links:HoloclaraHuman Genome project Diary of a worm - Doreen Cronin Wildlife of Our Bodies - Rob DunnSuzanne Lee  Ep Glennis Mehra EpEllen Jorgensen EpInnolabsNucleate Biolabs NYU LangoneGenspaceBiotech Without Borders Newlab Climate Week Event - sign up and get tickets now! Interstellar Comet Moving Through Our Solar SystemTopics Covered: immune system, biotherapeutics, worms, evolution, helminthic immunomodulation, medicine, pharmaceuticals  Have a question or comment? Message us here:Text or Call (804) 505-5553Instagram  / Twitter / LinkedIn / Youtube / Grow Everything

In this episode of Investor Connect, Hall Martin welcomes Uli Chettiapally, a distinguished physician, researcher, and healthcare innovator from Burlingame in the San Francisco Bay Area. Chettiapally shares his journey and expertise in driving physician-led innovation and collaboration through his firm, Innovator MD. He discusses how frontline medical professionals can identify unmet clinical needs and develop scalable solutions with the support of specialized education and networking opportunities provided by Innovator MD.  The conversation delves into the challenges and opportunities in funding healthcare startups, the role of AI and data in improving patient outcomes, and the importance of involving physicians early in the innovation process for realistic and effective healthcare solutions. Chettiapally also highlights his new venture, Sirica Therapeutics, aimed at revolutionizing autism treatment, and urges listeners to connect with him on LinkedIn for further collaborations.   Visit InnovatorMD & Sirica Therapeutics at   Reach out to at     _______________________________________________________ For more episodes from Investor Connect, please visit the site at:    Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

How do we embrace the unknowability of being alive?...Today, Abbie and Lois explore social therapeutics and performance activism as avenues for “performing beyond ourselves,” embracing life as play (and play as life), and creating stages- not of development- but, for development. ...As director of the East Side Institute, the research and education center for social therapeutics and performance activism, Lois Holzman has broadened its reach globally across geographical and practice/profession boundaries. As both academic scholar and popular writer, her work builds on the insights of Lev Vygotsky and Ludwig Wittgenstein, particularly on “language-ing” as relational activity, as an important component of an expended practical critique of the individualistic bio-medical model of emotional distress. Lois is the author of A Developmentalist's Guide to Better Mental Health: Navigating Everyday Life Dilemmas....Stories Lived. Stories Told. is created, produced & hosted by Abbie VanMeter.Stories Lived. Stories Told. is an initiative of the CMM Institute for Personal and Social Evolution....Music for Stories Lived. Stories Told. is created by Rik Spann....⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Explore all things Stories Lived. Stories Told. here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Explore all things CMM Institute here.

EPIsode 37 - Lauren Storch - Nutrition in Exocrine Pancreatic Insufficiency (EPI) and TPIAT (you see what we did there)In this episode of Nutrition Pearls: the Podcast, co-hosts Jen Smith and Nikki Misner speak with Lauren Storch on nutrition in patients with exocrine pancreatic insufficiency (EPI). Lauren works as a registered dietitian at Nationwide Children's Hospital, in Columbus Ohio, in the GI department working in both the inpatient and outpatient settings. She earned her undergraduate degree from Indiana University and her master's degree from The Ohio State University. Lauren has 11 years of experience in pediatric GI nutrition and is a Board Certified Specialist in Pediatric Nutrition. She has a wide variety of clinical interests all under the GI umbrella working with all the specialty centers within GI including the Pancreas and Liver centers.   Lauren enjoys seeing patients with all different GI conditions and needs, however she has a special interest in nutrition and EPI. When she is not working, she enjoys spending time with her husband, 2.5 year old daughter and 12 year old Corgi. Nutrition Pearls is supported by an educational grant from Mead Johnson Nutrition.Resources:Freeman et al. Medical Management of Chronic Pancreatitis in Children: A Position Paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Pancreas Committee, JPGN. 2021;72(2):324-340.Taylor CJ et al.ESPGHAN and NASPGHAN Report on the Assessment of Exocrine Pancreatic Function and Pancreatitis in Children. JPGN. 2015;61(1):144-153.Sankararaman S et al. Exocrine Pancreatic Insufficiency in Children – Challenges in Management. Pediatric Health, Medicine and Therapeutics. 2023;14:361–378. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st centuryTrang T, Chan J, Graham DY. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century. World J Gastroenterol 2014;20(33):11467-11485. -has photos of enzymes for size reference - Nathan JD, et al. The Role of Surgical Management in Chronic Pancreatitis in Children: A Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Pancreas Committee. JPGN. 2022;74: 706–719.https://pancreasfoundation.org/patient-resources/camp-hope/Produced by: Corey IrwinNASPGHAN - Council for Pediatric Nutrition Professionalscpnp@naspghan.org

In this episode of From the Helm, Grady Wulff sits down with Cynata Therapeutics (ASX:CYP) CEO, Kilian Kelly, to discuss the company's pioneering work in stem cell and regenerative medicine. Kilian shares insights on Cynata's mesenchymal stromal cell (MSC) platform, its unique “one donor, one time” approach, the path to commercialisation, and what investors can expect in the coming year.In this interview, Grady covers:(0:29) an introduction to Cynata and its core technology(1:05) the role and importance of mesenchymal stromal cells (MSCs)(2:06) how Cynata addresses the challenges facing MSC therapies(3:24) the game-changing “one donor, one time” model(8:09) Cynata's pipeline of assets in development(9:10) balance sheet strength and funding position(9:56) how Cynata compares with ASX peers(10:52) expected news flow over the next 12 months.This interview was recorded on Thursday, 11 September 2025.

What if a drug could help chemotherapy patients continue treatment without painful side effects? Hoth Therapeutics (NASDAQ: HOTH) is making that possible by developing innovative treatments that address unmet medical needs and help patients maintain their therapy safely.In this interview, CEO Robb Knie discusses HT001, the company's lead drug currently in Phase 2 trials for chemotherapy-induced rash, and HTKIT, which shows promise in cancer treatment. He also shares how the company is advancing programs for Alzheimer's and obesity, including an obesity drug licensed from the U.S. Department of Veterans Affairs.With a diversified pipeline, a patient-focused approach, and strategic use of AI to de-risk and accelerate development, Hoth Therapeutics is positioning itself as a biotech company to watch.Learn more about Hoth Therapeutics: https://hoththerapeutics.comWatch the full YouTube interview here: https://youtu.be/AYQa3g6dVLA?si=w_zDH0TaSxP3m6JiAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

It seems there are news stories every week about the accelerating pace of innovation in gene therapy, but only about 50 therapies have been approved so far by the US Food and Drug Administration. Our guest today, Dr. Bobby Gaspar, leads a UK-based biotech company, Orchard Therapeutics, that developed one of those treatments using gene-modified stem cells in your blood that self-renew, so a single administration can give you potentially a lifelong effect. “Our approach is about correcting those hematopoietic stem cells and allowing them to give rise to cells that can then correct the disease,” explains Dr. Gaspar.  The therapy in focus is lenmeldy, the first approved treatment for metachromatic leukodystrophy, also known as MLD, a devastating inherited disorder that affects roughly 600 children worldwide. But Dr. Gaspar is optimistic that learnings from Orchard's work on MLD could be useful in treating much more common disorders including frontotemporal dementia, Crohn's disease and others. This highly informative conversation with host Lindsey Smith also explores the importance of newborn screening, community collaboration in advancing clinical trials for rare diseases, and a future in which each gene therapy will be used as a tool for specific applications.  “There will be many gene therapies available, some of which will become the standard of care for certain diseases, but it won't be for every disease.”Mentioned in this episode:Orchard Therapeutics If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

We love to hear from our listeners. Send us a message.On episode 111 of Cell & Gene: The Podcast, Host Erin Harris talks to Ernexa Therapeutics' President and CEO, Sanjeev Luther, about how the company is advancing cell therapy innovation for cancer and autoimmune disease through engineered induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs). Luther shares how Ernexa's synthetic, standardized, off-the-shelf iMSCs are designed to overcome historic hurdles in MSC therapy, including variability, scalability, and manufacturing complexity, by leveraging master cell banks, precise gene editing, and novel product engineering. He also shares insights into the process of developing pro- and anti-inflammatory iMSCs for oncology and autoimmunity.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Can regenerative medicine move beyond managing symptoms to actually restore natural hearing?Brian Taylor speaks with Simon Chandler, CEO of Rinri Therapeutics, about the company's pioneering cell therapy for hearing loss. They discuss Rincell-1, Rinri's first-in-human clinical trial, and how regenerative medicine could complement or even surpass today's treatments like hearing aids and cochlear implants.The conversation also explores Rinri's innovative surgical delivery approach, trial design, and future pipeline, including next-generation therapies aimed at restoring hair cells. Chandler shares his vision for how regenerative medicine could reshape hearing care and open the door to restoring hearing for millions worldwide.Learn more about Rinri and Rincell-1 at: https://www.rinri-therapeutics.comBe sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.- https://x.com/WeekinHearing- https://www.instagram.com/thisweekinhearing/- https://www.linkedin.com/company/this-week-in-hearingVisit us at: https://hearinghealthmatters.org/thisweek/

Sigyn Therapeutics, Inc. has announced plans to initiate a multi-site clinical feasibility study evaluating its breakthrough Sigyn Therapy™ in patients with high-risk cardiovascular disease, the world's leading cause of death, according to the World Health Organization. CEO Jim Joyce told Proactive that Sigyn Therapy is a first-in-class whole-blood adsorption technology designed to be deployed on existing dialysis machines already found in hospitals and clinics worldwide. Unlike conventional approaches, the therapy is engineered to address multiple drivers of cardiovascular disease progression in a single treatment. Specific to CVD, Sigyn Therapy has been shown to reduce circulating inflammatory molecules that accelerate disease progression, while simultaneously targeting cholesterol-transporting lipoproteins that are responsible for heart attacks, strokes, and other major adverse cardiovascular events. Building on encouraging results from pre-clinical in vitro studies, the company is expanding its feasibility study protocol to include the measurement of lipoprotein reduction during therapy. This will allow investigators to quantify the dual-action benefit of Sigyn Therapy in reducing both inflammation and lipid-related risks. The upcoming feasibility study will be a critical step toward the company's long-term goal: advancing to a pivotal efficacy study required for potential regulatory clearance and commercialization. If successful, Sigyn Therapy could represent a transformative advancement in the treatment of cardiovascular disease by integrating seamlessly into existing hospital infrastructure while addressing some of the most urgent unmet needs in cardiac care. Joyce added that the company is in the process of modifying its Investigational Device Exemption (IDE) for submission to the FDA, to formally include Ldl-c and Lp(a) reduction as observational endpoints. #proactiveinvestors #sigyntherapeuticsinc #otcqb #sigy #CardiovascularDisease #Dialysis #SigynTherapeutics #MedicalDevices #BloodPurification #ClinicalTrials #Lipoproteins #StatinAlternative #EndStageRenalDisease #FDAReview

Welcome back! Today, we have renowned guest Dr. Bruce Perry, one of the world's most influential child psychiatrists, to talk to us about his approach to trauma. We will go over Dr. Perry's Neurosequential Model of Therapeutics, which integrates neuroscience with child development. Dr. Perry is also a respected author, co-writing books like The Boy Who Was Raised As a Dog, Born for Love: Why Empathy is Essential and Endangered, as well as What Happened to You? Conversations on Trauma, Resilience and Healing.Dr. Perry's Website: https://www.bdperry.com/Dr. Perry's Books: https://www.amazon.com/Books-Bruce-Perry/s?rh=n%3A283155%2Cp_27%3ABruce%2BPerryDr. Perry's Youtube Channel: https://www.youtube.com/@infonmn326

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein, it's a bit of a word salad, but what we're trying to achieve here is finding unique binding sites on proteins that are sort of away from the active site of that protein." "So, a lot of physics calculations go into these binding site calculations. The idea is to complete these quickly during the screening of hundreds or thousands of compounds. This process takes 10 to 15 minutes to run a set of computations and determine if a particular molecule is a fit for a specific protein. If that takes 10 or 15 minutes per compound, it's not a very big deal to go to that library if you need to get through billions, trillions of those compounds, and you need that computational speed to really fire up." "We are able to speed up those calculations from, let's say, 10 minutes to milliseconds. You can screen through much larger numbers of compounds and potentially even construct new molecules that are not known to the public domain, which would be a real key innovation." "What we think we have in our lead program, which is GT-02287, another molecule that was discovered through our application of Magellan. What we hope we have in GT-02287 is a disease-modifying approach to Parkinson's. Up until now, the only available treatments for Parkinson's are really just focused on the symptoms and allaying the severity of the symptoms." #Parkinsons #ParkinsonsDisease #AI #DrugDiscovery #GAINtherapeutics #DiseaseModification gaintherapeutics.com Download the transcript here

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein, it's a bit of a word salad, but what we're trying to achieve here is finding unique binding sites on proteins that are sort of away from the active site of that protein." "So, a lot of physics calculations go into these binding site calculations. The idea is to complete these quickly during the screening of hundreds or thousands of compounds. This process takes 10 to 15 minutes to run a set of computations and determine if a particular molecule is a fit for a specific protein. If that takes 10 or 15 minutes per compound, it's not a very big deal to go to that library if you need to get through billions, trillions of those compounds, and you need that computational speed to really fire up." "We are able to speed up those calculations from, let's say, 10 minutes to milliseconds. You can screen through much larger numbers of compounds and potentially even construct new molecules that are not known to the public domain, which would be a real key innovation." "What we think we have in our lead program, which is GT-02287, another molecule that was discovered through our application of Magellan. What we hope we have in GT-02287 is a disease-modifying approach to Parkinson's. Up until now, the only available treatments for Parkinson's are really just focused on the symptoms and allaying the severity of the symptoms." #Parkinsons #ParkinsonsDisease #AI #DrugDiscovery #GAINtherapeutics #DiseaseModification gaintherapeutics.com  Listen to the podcast here

In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.

Nimbus Therapeutics is transforming drug discovery with computational chemistry and AI to design small molecules that precisely target disease. CEO Abbas Kazimi, who took the helm in March, is driving a “fail fast” approach that balances discipline with innovation. He joins Inside the ICE House to share how Nimbus is scaling its pipeline and shaping the future of precision medicine.

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Joel Stanley, CEO of Ajna Biosciences. We explore the promise and challenges of botanical drugs, focusing on Ajna Biosciences' approach to developing therapeutics derived from plants such as cannabinoids and psychedelics. Joel reflects on his experience co-founding Charlotte's Web during the early medical cannabis movement and how that shaped his perspective on botanical drug development. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Dave and Brandon dive into Nvidia's recent earnings report. Plus, LENZ Therapeutics and the European EV Market

In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases. Cardiol's lead asset, CardiolRx™, is currently in: A Phase 3 trial (Maverick Study) for recurrent pericarditis, enrolling patients at world-leading centers including the Cleveland Clinic, Mayo Clinic, and Mass General. A Phase 2 trial (ARCHER Study) for acute myocarditis, where recently released top-line results showed promising impacts on heart size and function. We also cover: The company's orphan drug designation from the FDA and its implications for market exclusivity. Development of CRD-38, a next-generation therapy designed for heart failure - a market with multi-billion-dollar potential. Cardiol's capital position, with funding secured well into 2026. Key upcoming milestones for investors, including full data presentations, trial updates, and potential pharma partnerships.   Please email me any further questions you have for David. My email address is Fleck@kereport.com.  Click here to learn more about Cardiol Therapeutics.

We love to hear from our listeners. Send us a message. On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

You can also watch the video version of this episode on dvm360.com Alice Jeromin, RPh, DACVD—Before earning her DVM degree from The Ohio State University, Jeromin graduated from the University of Toledo with a BS in Pharmacy and practiced as a hospital pharmacist. She completed her veterinary dermatology residency with Patrick Breen and dermatopathology training at Procter & Gamble, Miami Valley Labs, as well as a fellowship in human dermatology at Metro Health Medical Center, Cleveland, Ohio with Bryan Davis. Jeromin is currently an adjunct professor at Case Western Reserve University, lecturer at Northeast Ohio College of Pharmacy, and former practice owner of Veterinary Allergy & Dermatology, Inc. She is a former member-at-large on AVMA's Council on Biologicals and Therapeutics as chairman of the supplements and compounding committees. Along with publishing in human and veterinary journals, she authored the dermatology chapter in “Pharmacotherapeutics for Veterinary Dispensing”. Her interests include human-animal comparative dermatology and skin lipid research with publications in both areas.  Because of her pharmacist background of counseling patients, she is a strong believer in client education and maintains her website, www.purrfectpet.com, for clients to be educated with evidence-based information as well as an upcoming podcast "Speaking of Pets" The podcast is geared toward pet owners of allergic pets to provide them with accurate, evidence-based information.

Dr. Steven Quay, Chairman and CEO of Atossa Therapeutics, is dedicated to addressing unmet needs in breast cancer prevention and treatment. Dense breasts are a significant risk factor for breast cancer, and Atossa's lead drug candidate has shown effectiveness in reducing breast density and lowering the risk of cancer. This dual-action drug blocks estrogen receptor signaling and induces programmed cell death in cancer cells, potentially offering a more effective and more tolerable treatment option. Steven explains, "So we are very focused on breast cancer to the point that Princess of Atossa, the company is named after, was the first woman in recorded history with breast cancer about four 50 BC. She was the wife of Darius the Great, who had the Persian Empire, the largest piece of real estate before the Roman Empire. And she had a breast lesion. It was documented that her slave cauterized it with a hot poker from the fire. We didn't get a follow-up from that, but anyway, we are dedicated to all the women, including her, and since then, who have been dealing with breast cancer."  "So it's a very interesting molecule. We call it a Janus molecule. Janus is the two-faced goddess. In this case, it is two-faced in a positive fashion because she addresses two different ways that cancer cells control themselves to drive the growth. Its major activity is to block estrogen binding to the estrogen receptor. So, as I said at the beginning, if 75% of all breast cancers are driven by estrogen, our drug is going to really nail 75% of all breast cancers. But then it gets even more exciting because it also has a second activity in another pathway in cancer driving called PKC beta."  #AtossaTherapeutics #BreastCancer #Cancer #DenseBreasts #Estrogen atossatherapeutics.com  Listen to the podcast here

Dr. Steven Quay, Chairman and CEO of Atossa Therapeutics, is dedicated to addressing unmet needs in breast cancer prevention and treatment. Dense breasts are a significant risk factor for breast cancer, and Atossa's lead drug candidate has shown effectiveness in reducing breast density and lowering the risk of cancer. This dual-action drug blocks estrogen receptor signaling and induces programmed cell death in cancer cells, potentially offering a more effective and more tolerable treatment option. Steven explains, "So we are very focused on breast cancer to the point that Princess of Atossa, the company is named after, was the first woman in recorded history with breast cancer about four 50 BC. She was the wife of Darius the Great, who had the Persian Empire, the largest piece of real estate before the Roman Empire. And she had a breast lesion. It was documented that her slave cauterized it with a hot poker from the fire. We didn't get a follow-up from that, but anyway, we are dedicated to all the women, including her, and since then, who have been dealing with breast cancer."  "So it's a very interesting molecule. We call it a Janus molecule. Janus is the two-faced goddess. In this case, it is two-faced in a positive fashion because she addresses two different ways that cancer cells control themselves to drive the growth. Its major activity is to block estrogen binding to the estrogen receptor. So, as I said at the beginning, if 75% of all breast cancers are driven by estrogen, our drug is going to really nail 75% of all breast cancers. But then it gets even more exciting because it also has a second activity in another pathway in cancer driving called PKC beta."  #AtossaTherapeutics #BreastCancer #Cancer #DenseBreasts #Estrogen atossatherapeutics.com Download the transcript here

On this episode Gil Bashe welcomes Craig Martin—former acting CEO of Global Genes and founder/CEO of the Orphan Therapeutics Accelerator—about the urgent need to rescue clinically promising drugs for rare and ultra-rare diseases. Craig shares how his nonprofit model uses AI, CDMOs, CROs, and alternative funding to de-risk shelved therapies and transform them into treatments for patients with unmet needs. including context on systemic inequities and the human cost of stalled innovation. He describes a startling trend: when capital dries up or regulations shift, life-saving drug programs get shelved—not because of safety or efficacy issues, but due to dilution in business incentives. Among those left behind are rare disease candidates that patients and families know work, but simply become financially unviable. Martin joins us to unpack a pressing challenge in rare disease therapeutics: promising clinical‑stage drug programs that have been shelved—not for lack of science, but due to shifting capital and incentives. Through his nonprofit model at OTXL, he's pioneering an entirely new approach to rescue these assets and deliver real impact. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Download the transcript here

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Listen to the podcast here

From the moment he walked out of a cinema showing Jurassic Park aged 10, Samir Ounzain knew he wanted to work with DNA. That early obsession turned into a career dedicated to understanding the 98% of our genome that doesn't code for proteins - what's often referred to as the “dark genome.” In this episode, Samir shares the personal and scientific journey that led to founding HAYA Therapeutics, a Biotech trailblazing an entirely new approach to treating common and chronic diseases. He explains how HAYA builds backwards from unmet patient needs, and forwards with a first-principles view of biology - putting the cell, not the target, at the centre of drug discovery. This is a story about biology, yes - but it's also about clarity, courage, and commitment to a new model of Biotech.

Tech taking it on the chin, as big tech sells off in today's session. The Mag-7 names pulling down the space, and the semi stocks feeling the heat. Plus A biotech bummer. Shares of Viking Therapeutics tanking after the company posted disappointing weight loss drug pill trial data. What it means for the company's next move, and the impact it could have on potential M&A action.Fast Money Disclaimer

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com A key takeaway from this interview is that the most effective path to value-based care starts with building trust, proving outcomes, and aligning your pitch with what payers already prioritize. In this episode, David Ricupero,  Director of Business Development at Affect Therapeutics and Creator of the Out-of-Pocket Course: How to Contract with Payors, explains the full journey of payer contracting, from initial applications to advanced value-based agreements. He covers how to join payer networks, manage closed systems, and prepare key documents and timelines. David explores various value-based care models, illustrating how risk and complexity grow from pay-for-performance to full capitation, and highlights the importance of combining traditional applications with strategic conversations. He also offers practical tips for avoiding “payer purgatory,” identifying payer goals, and asking the right questions during shared savings negotiations. Tune in and learn how to navigate the nuances of payer-provider relationships and set up sustainable, rewarding contracts that truly expand access to care! Resources: Connect with and follow David Ricupero on LinkedIn. Follow Affect Therapeutics on LinkedIn and explore their website.  Register for the “How to Contract with Payors” course here.

Why the Fed could skip a September cut altogether, despite higher inflation data. BTIG makes the case for sticking with Viking Therapeutics despite disappointing weight loss drug trial data. Plus, the laggards our traders says to buy now.  

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

We love to hear from our listeners. Send us a message. On this week's episode, Milan Kalawadia, CEO, North America, Dr. Reddy's Laboratories, and Arun Swaminathan, Ph.D., CEO, Coya Therapeutics discuss their unique partnership to develop COYA 302, a novel dual-mechanism immunotherapy for the treatment of ALS. The partnership pairs Coya's scientific expertise with Dr. Reddy's manufacturing and commercialization capabilities, putting Coya in a financial position to advance development activities and commercialize COYA 302 upon FDA approval, and providing Dr. Reddy's -- a generics, biosimilars, API, and OTC manufacturer -- with an opportunity to pivot into innovative branded products. Kalawadia and Swaminathan discuss their pathways to the CEO role at each company, respectively, how the partnership came together, ongoing FDA engagement, and what COYA 302 could mean for patients with ALS. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

On August 5, Health Secretary Robert F. Kennedy Jr. announced that the Department of Health and Human Services would terminate almost $500 million in mRNA vaccine development grants and contracts, affecting 22 projects. Biologist and mRNA researcher Jeff Coller joins Host Ira Flatow to talk about what this move means for future mRNA research in the US beyond these immediate projects.Plus, reporter Casey Crownhart joins Ira to discuss the latest in climate news, including flooding in Juneau, Alaska; how Ford is pursuing further electric vehicle manufacturing despite federal roadblocks; and a startup using Earth itself as a giant battery.Guests:Dr. Jeff Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University.Casey Crownhart is a senior climate reporter for MIT Technology Review in New York, New York.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

In this episode, Jacob sits down with Joshua Meier, co-founder of Chai Discovery and former Chief AI Officer at Absci, to explore the breakthrough moment happening in AI drug discovery. They discuss how the field has evolved through three distinct waves, with the current generation of companies finally achieving success rates that seemed impossible just years ago.  The conversation covers everything from moving drug discovery out of the lab and into computers, to why AI models think differently than human chemists, to the strategic decisions around open sourcing foundational models while keeping design capabilities proprietary. It's an in-depth look at how AI is fundamentally changing pharmaceutical innovation and what it means for the future of medicine. Check out the full Chai-2 Zero-Shot Antibody report linked here: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf [0:00] Intro[2:10] The Evolution of AI in Drug Discovery[6:09] Current State and Future of AI in Biotech[11:15] Challenges and Modalities in Therapeutics[15:19] Data Generation and Model Training[23:59] Open Source and Model Development at Chai[28:35] Protein Structure Prediction and Diffusion Models[30:57] Open Source Models and Their Impact[35:41] How Should Chai-2 Be Used?[39:34] The Future of AI in Pharma and Biotech[43:51] Key Milestones and Metrics in AI-Driven Drug Discovery[48:24] Critiques and Hesitation[55:06] Quickfire With your co-hosts: @jacobeffron - Partner at Redpoint, Former PM Flatiron Health @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @jordan_segall - Partner at Redpoint

Rick Geoffrion, Founder and CEO of Cyrano Therapeutics, is developing a drug to restore olfactory function due to post-viral loss of smell and taste. As a result of COVID-19, there has been a significant increase in the number of people affected by long-term smell and taste loss, with no effective pharmaceutical options previously available. Smell loss can also be an early indicator of neurodegenerative conditions, suggesting future applications of the intranasal spray that aims to directly restore function to the olfactory receptor neurons. Rick explains, "Taste and smell have a really strong connection, actually. First of all, they're two out of the five basic senses that we have as human beings. When you lose your sense of smell, people actually perceive that they've lost about 80% of their sense of taste. Now, technically, you're not losing your sense of taste. We actually just give our tongue too much credit. Our tongue is able to detect sweet, sour, salty, bitter, and umami. That's all it detects, and it detects them really in light monotone that are about 80% less intense if you've lost your sense of smell. In addition, if you no longer have your sense of smell, what you've really lost is the ability to detect flavor in food. So, to tell the difference between a peach, a pear, and a strawberry, maybe you'll tell that visually, but to tell it from a flavor perspective, you completely lose that ability.    "There really are no significant therapies to treat the condition right now. Essentially, if you've lost your sense of smell, a physician may recommend that you use smell training, which is essentially the regular smelling of intense essential oils, and they really haven't been shown to significantly treat or cure a chronic smell loss condition. It is thought that if your body is spontaneously recovering, say within those first few months, if you do undergo smell training, you may accelerate that recovery. But other than that, there's certainly no gold standard treatment or no significant treatments available right now, and no pharmaceuticals in the pipeline other than CYR-064, which is being developed by Cyrano." #CyranoTherapeutics #Olfactory #LongCOVID #PostViralLoss #IntranasalSpray #SmellandTaste #LongTermSmellLoss cyranotherapeutics.com Download the transcript here

In this episode, Dr. Rachel welcomes Dr. Karen Davidson, a trailblazer in airway diagnostics and a disruptor in the world of nasal health. Dr. Karen takes us through her unconventional 34-year journey,from critical care flight nurse to patented inventor and airway educator,revealing how we've misunderstood nasal function for decades.Together, they unravel the science behind nasal resistance, debunk myths about CPAP therapy, and dive into why nasal function,not volume determines breathing quality. Dr. Karen shares how she pioneered the Daphne Score and the concept of pseudo-UARS, offering a data-driven approach to understanding airflow, pressure, and airway compensation.We also explore the systemic effects of nasal resistance,from heart rate variability in athletes to sleep-disordered breathing in children misdiagnosed with ADHD. With bold insights and a refreshing dose of cynicism, Dr. Karen challenges the current medical system and encourages collaboration across specialties to improve patient care.Highlights:Dr. Karen's journey from nurse to airway innovator and educatorWhy nasal function, not just nasal breathing mattersHow nasal resistance affects posture, speech, sleep, and heart rateThe creation and science behind the Daphne Score and airway AIUnderstanding pseudo-UARS and overexpansion risks in orthodonticsCPAP intolerance and why it often fails due to undiagnosed nasal resistanceThe flawed "disease management" model in healthcareWhy sleep doesn't disorder breathing, breathing disorders sleepNasal function as a key factor in ADHD misdiagnosis and childhood airway issuesFunctional diagnostics: From facial analysis to RhinoManometryThe neurological connection between nasal resistance and tongue functionThe importance of individualized treatment based on nasal flow and pressureThe emerging International Society of Airway Function Diagnostics & TherapeuticsAbout the Guest:Dr. Karen Fields-Lever is a critical care flight nurse, airway diagnostics expert, and creator of the patented Daphne Score software used to analyze nasal resistance and flow. With over 8,000 cases of ENT experience, she brings a rare blend of clinical and industry insight to breathing science. A published author and educator, Dr. Karen has pioneered flow-based orthodontics, Maverick nasal exams, and teaches across multiple specialties, including dentistry, ENT, chiropractic, and physical therapy. She is the founder of the International Society of Airway Function Diagnostics and Therapeutics, and her mission is clear: redefine how we measure, interpret, and treat the airway.Resources MentionedWebsite | karenparkerdavidson.comFounder of |International Society of Airway Function, Diagnostics, & TherapeuticsInstagram | @_thenoseknowsBooks MentioneDAmazon Link

In this Huberman Lab Essentials episode, my guest is Dr. Matthew Johnson, PhD, a senior researcher for the Center of Excellence for Psilocybin Research and Treatment at Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics. We explore the science and therapeutic potential of psychedelic medicine, including psilocybin, MDMA and LSD. We discuss how these substances can profoundly alter perception and self-identity, providing long-lasting relief from depression, addiction and trauma when used in controlled clinical settings. We also discuss microdosing and emerging research on psychedelics' potential to support recovery from neurological injuries. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman BetterHelp: https://betterhelp.com/huberman Timestamps 00:00:00 Matthew Johnson; Psychedelics 00:01:44 Different Classes of Psychedelics 00:04:33 Psychedelics & Altering Models 00:06:18 Sponsor: David 00:07:33 LSD, Psylocibin & Serotonin 00:09:55 Psychedelic Clinical Trials 00:13:40 Therapy, Trust, Psychedelics 00:16:47 Letting Go & Psychedelic Experience, Self-Representation, Lasting Changes 00:22:31 Sponsors: AG1 & BetterHelp 00:25:26 MDMA, Dopamine & Serotonin; Bad Trips & Transcendental Experience 00:28:49 Dangers of Psychedelics 00:31:11 Microdosing Psychedelics, Antidepressant 00:35:27 Head Injuries, Psychedelics, Depression 00:38:29 Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Kirk Huntsman, Chairman, CEO, and Co-Founder of Vivos Therapeutics, is focused on the connection between obstructive sleep apnea and Alzheimer's disease, the challenges of diagnosing sleep apnea, and the importance of sleep testing in treating the root causes of sleep disorders. The Vivos oral appliance is a non-invasive way to address the breathing disorder OSA and resulting sleep issues. Proper nasal breathing and airway development from a young age can help prevent the onset of sleep apnea and help preserve brain health. Kirk explains, "Sleep apnea is an interesting condition that has only been actively researched for the last 60 years. It was really only identified and started showing up in the medical literature in the mid-1960s. And so we really have about a 60-year run at trying to figure out what this condition is, what it affects, what's comorbid with it, etc. We're now pushing 40 plus conditions, which are comorbid with sleep apnea, and every time we find another condition that is coexistent with sleep apnea or that is found in connection with sleep apnea, we just expand the horizon for that and we learn more about the sort of the biomechanical and the biological processes that are at work that drive the connection between these two. And you mentioned one of the main ones now that we've known about for a while, but the connection between obstructive sleep apnea in particular and Alzheimer's." "What we know is that there's a drainage system on the brain. Our brains need to get into a deep state of rest, and it's called REM sleep. And there are other parts to this. I'll keep it really high level, but the bottom line is that our brains flush. There's a sewage system that basically flushes the toxins out of our brains. It's called the glymphatic system. And the glymphatic system needs to be able to function, and in order to function, the patient has to be in a state of deep sleep. And so if sleep apnea has interrupted that sleep and caused various arousals or various interruptions to avoid a patient arriving at that, what happens is that the brain is not able to flush the toxins out of the brain, and those toxins build up." #VivosTherapeutics #SleepApnea #ObstructiveSleepApnea #OSA #SleepDisorders #CognitiveDecline #Alzheimers #OSATreatment #MedicalDevice  vivos.com Listen to the podcast here  

Kirk Huntsman, Chairman, CEO, and Co-Founder of Vivos Therapeutics, is focused on the connection between obstructive sleep apnea and Alzheimer's disease, the challenges of diagnosing sleep apnea, and the importance of sleep testing in treating the root causes of sleep disorders. The Vivos oral appliance is a non-invasive way to address the breathing disorder OSA and resulting sleep issues. Proper nasal breathing and airway development from a young age can help prevent the onset of sleep apnea and help preserve brain health. Kirk explains, "Sleep apnea is an interesting condition that has only been actively researched for the last 60 years. It was really only identified and started showing up in the medical literature in the mid-1960s. And so we really have about a 60-year run at trying to figure out what this condition is, what it affects, what's comorbid with it, etc. We're now pushing 40 plus conditions, which are comorbid with sleep apnea, and every time we find another condition that is coexistent with sleep apnea or that is found in connection with sleep apnea, we just expand the horizon for that and we learn more about the sort of the biomechanical and the biological processes that are at work that drive the connection between these two. And you mentioned one of the main ones now that we've known about for a while, but the connection between obstructive sleep apnea in particular and Alzheimer's." "What we know is that there's a drainage system on the brain. Our brains need to get into a deep state of rest, and it's called REM sleep. And there are other parts to this. I'll keep it really high level, but the bottom line is that our brains flush. There's a sewage system that basically flushes the toxins out of our brains. It's called the glymphatic system. And the glymphatic system needs to be able to function, and in order to function, the patient has to be in a state of deep sleep. And so if sleep apnea has interrupted that sleep and caused various arousals or various interruptions to avoid a patient arriving at that, what happens is that the brain is not able to flush the toxins out of the brain, and those toxins build up." #VivosTherapeutics #SleepApnea #ObstructiveSleepApnea #OSA #SleepDisorders #CognitiveDecline #Alzheimers #OSATreatment #MedicalDevice vivos.com Download the transcript here

We love to hear from our listeners. Send us a message. On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/